Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
CRH
CRH
|
$150M |
| 2 |
Kenvue
KVUE
|
$98.9M |
| 3 |
Sempra
SRE
|
$60.4M |
| 4 |
Copart
CPRT
|
$52.4M |
| 5 |
Textron
TXT
|
$50.7M |
Top Sells
| 1 |
Apple
AAPL
|
$1.12B |
| 2 |
Microsoft
MSFT
|
$890M |
| 3 |
Amazon
AMZN
|
$463M |
| 4 |
NVIDIA
NVDA
|
$425M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$316M |
Sector Composition
| 1 | Technology | 29.44% |
| 2 | Healthcare | 13.62% |
| 3 | Consumer Discretionary | 11.97% |
| 4 | Industrials | 9.14% |
| 5 | Communication Services | 8.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNSL
2476
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $570K | ﹤0.01% |
166,647
+4,800
| +3% | +$16.4K |
|
2477
Dyne Therapeutics
DYN
$1.91B
| $569K | ﹤0.01% |
63,500
| – | – |
|
2478
Summit Therapeutics
SMMT
$17.9B
| $568K | ﹤0.01% |
303,800
| – | – |
|
|
AGTI
2479
DELISTED
Agiliti, Inc.
AGTI
| $567K | ﹤0.01% |
87,400
| – | – |
|
|
ME
2480
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $567K | ﹤0.01% |
579,800
+14,000
| +2% | +$13.7K |
|
2481
Babcock & Wilcox
BW
$217M
| $564K | ﹤0.01% |
133,900
| – | – |
|
2482
Phibro Animal Health
PAHC
$1.42B
| $561K | ﹤0.01% |
43,900
| – | – |
|
2483
Enliven Therapeutics
ELVN
$1.23B
| $556K | ﹤0.01% |
40,673
-8,500
| -17% | -$116K |
|
2484
iTeos Therapeutics
ITOS
| $554K | ﹤0.01% |
50,600
| – | – |
|
2485
Olaplex Holdings
OLPX
$947M
| $553K | ﹤0.01% |
283,800
| – | – |
|
2486
Semrush
SEMR
$1.14B
| $553K | ﹤0.01% |
65,100
-12,200
| -16% | -$104K |
|
2487
Funko
FNKO
$176M
| $551K | ﹤0.01% |
72,000
| – | – |
|
2488
Innoviz Technologies
INVZ
$315M
| $549K | ﹤0.01% |
281,400
+45,100
| +19% | +$87.9K |
|
2489
Lindblad Expeditions
LIND
$781M
| $548K | ﹤0.01% |
76,141
+1,600
| +2% | +$11.5K |
|
2490
8x8 Inc
EGHT
$265M
| $548K | ﹤0.01% |
217,500
-28,700
| -12% | -$72.3K |
|
2491
Vanda Pharmaceuticals
VNDA
$282M
| $546K | ﹤0.01% |
126,300
+4,100
| +3% | +$17.7K |
|
2492
Ribbon Communications
RBBN
$717M
| $543K | ﹤0.01% |
202,674
| – | – |
|
2493
Vivid Seats
SEAT
$108M
| $542K | ﹤0.01% |
84,500
+4,100
| +5% | +$26.3K |
|
2494
American Well
AMWL
$113M
| $542K | ﹤0.01% |
463,200
+10,500
| +2% | +$12.3K |
|
|
EBIX
2495
DELISTED
Ebix Inc
EBIX
| $537K | ﹤0.01% |
54,400
+1,100
| +2% | +$10.9K |
|
2496
Arcutis Biotherapeutics
ARQT
$1.87B
| $537K | ﹤0.01% |
101,200
+9,100
| +10% | +$48.3K |
|
2497
Soho House & Co
SHCO
$1.72B
| $537K | ﹤0.01% |
77,500
+12,800
| +20% | +$88.7K |
|
2498
Stitch Fix
SFIX
$664M
| $536K | ﹤0.01% |
155,400
+3,700
| +2% | +$12.8K |
|
2499
Seres Therapeutics
MCRB
$167M
| $536K | ﹤0.01% |
225,000
+5,400
| +2% | +$12.9K |
|
2500
Distribution Solutions Group
DSGR
$1.47B
| $531K | ﹤0.01% |
20,404
+10,202
| +100% | +$265K |
|